IL-PRICEFX
18.1.2022 15:32:10 CET | Business Wire | Press release
Pricefx , the global leader in cloud pricing software, today announced it closed the best quarter in company history due to strong customer and partner traction in 2021. With 26 deals closed in Q4 2021 and 34 new enterprise customers added in 2021, the company ended the year with 45% year-over-year annual recurring revenue (ARR) growth. Key new customers include American Tire Distributors, Extreme Networks, KeHe Distributors and Tamko Building Products. Additionally, Pricefx recorded 95% customer retention and closed 23 customer expansion deals.
In 2021, Pricefx increased revenue growth with SAP by 140% over 2020. The Advantage Pricefx partner program continued to drive significant return on investment in 2021 with at least one partner engaged on 70% of new customers signed through co-selling, influencing, and/or implementing the Pricefx solution. Several global system integrators, such as the KPMG German member firm, joined Pricefx’s ecosystem broadening the company’s reach and deepening its pricing expertise.
To support this growth, the company expanded its ranks by 11% in 2021, adding several key hires during the year. Ronak Sheth joined the company in May as President and Chief Revenue Officer. Toby Davidson was named Chief Product and Technology Officer in January, leading the development of several new product features throughout the year. In January, Pricefx partnered with Bain & Company to launch PricefxPlasma™ , the industry’s first big data powered benchmarking platform. To address the increased demand for AI-driven revenue growth, Pricefx introduced the industry’s first AI-powered market simulation solution in April. Pricefx also simplified its product offering around three core packages Plan , Price and Profit , showcased in the company’s recently updated website.
Pricefx also brought Doug Fuehne on board as Senior Vice President to lead the newly formed Pricefx Impact team. With more than two decades of experience in pricing and software, Fuehne joined Pricefx from Amazon where he was the Global Practice Lead, Manufacturing & Supply Chain for Amazon Web Services (AWS) and led the creation of AWS’ digital supply chain transformation methodology. Prior to that, he was the Head of Customer Success for Commercial Industries at Amazon Business where he led the ProServe implementation team for Amazon’s B2B distribution division. The Impact team works across the entire customer lifecycle to help customers identify the best solutions specific to their industry and strategic goals, understand and measure the value delivered, and grow the value obtained from Pricefx over time.
“Supply chain issues, pricing fluctuations and inflationary pressures across nearly every industry forced companies to find ways to adjust to a volatile market,” said Sheth. “Pricefx was able to help companies navigate these challenges and maintain its leadership position in the market surge for price optimization. Our industry-leading pricing solutions, ability to create a customized plan for customers to achieve profitable growth in record time, and relentless focus on customer satisfaction has led to a blockbuster year for the company, including new customer acquisitions and continued expansion into existing accounts.”
Pricefx was named a Chicago Best Mid-Sized Companies to Work For by Built In for the second year in a row. The company was also an SAP® Pinnacle Award finalist for the second year in a row; this year in the Partner of the Year – Endorsed Apps category. Continuing the back-to-back streak, Pricefx was named Product of the Year in the 2021 Sales and Marketing Technology Awards program, also known as The Sammys. The company was also awarded the Gold GLOBEE® for Configure Price Quote (CPQ) in the 2021 IT World Awards® and honored with a Silver Stevie® Award in the manufacturing business technology category of the 2021 American Business Awards®. The Global Business Tech Awards named Pricefx to its shortlist for Best SaaS Company of the Year and the SaaS Awards shortlisted Pricefx in two categories.
Follow Pricefx
LinkedIn: https://www.linkedin.com/company/price-f-x-/
Twitter: https://twitter.com/price_fx
About Pricefx
Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Based on cloud-native architecture, Pricefx delivers a complete price optimization and management platform that provides the industry’s fastest time-to-value and lowest total cost of ownership. Its innovative solution works for B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. For enterprises facing pricing challenges, Pricefx is the cloud pricing optimization, management, and CPQ platform to dynamically Plan, Price and Profit.
For more information, please visit www.pricefx.com .
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom